Tag Archives: BARDA

Blue Ribbon Study Panel Examines Surveillance and Detection Issues in Biodefense

Jim Greenwood

The Blue Ribbon Study Panel on Biodefense held the third of four meetings on Thursday, March 12, 2015. The goal of the Panel is to evaluate the United States’ level of preparedness for a natural or deliberate biological or chemical event and to develop actionable recommendations toward the aim of preparedness. The Blue Ribbon Study Panel on Biodefense will build off the work previously done by the 9/11 Commission and the Weapons of Mass Destruction Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: ,

The Hill: Will Support for Biomedical Research Be Dead on Arrival?

ebola

In an op-ed over at The Hill, Dr. Claire Pomeroy, an infectious disease specialist and president of the Albert and Mary Lasker Foundation, discusses an important question: “How is it that the United States, which has historically held the global lead in medical innovation, was caught flat-footed by Ebola?” Dr. Pomeroy points to a lack of federal funding for medical research as one of the primary culprits for our lack of effective Ebola answers, a Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Jim Greenwood Op-Ed: Time to Fund Medical Countermeasures against Threats like Ebola

Jim Greenwood

On Friday, The Hill published an op-ed from BIO President and CEO Jim Greenwood calling on Congressional appropriators to fully fund federal biodefense programs, which partner with industry to develop medical countermeasures against Ebola as well as other threats like smallpox, anthrax, and botulism toxin. President Obama’s supplemental Ebola funding request last week asked Congress to appropriate $157 million in funding for BARDA and $238 million for the National Institutes of Health to support Ebola Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

Nature Biotechnology: Outpaced by an outbreak

admin-ajax

The current issue of Nature Biotechnology contains an editorial on the response to the Ebola outbreak that is well-worth the read. The editors discuss some of the barriers which have slowed the development of Ebola medicines, including budgetary issues with federal programs designed to incentivize the development of medical countermeasures for threats like Ebola: We have no medicines to combat Ebola partly because of the time it takes to develop products—BARDA has been in existence Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

U-T San Diego Commentary: Lack of Preparedness to Ebola Is Symptom of Larger Disease

admin-ajax

Last week, the U-T San Diego published an op-ed by Betrand Liang, CEO of Pfenex Inc., a BIO member, arguing that our current lack of vaccines and therapies for Ebola is a symptom of a larger problem. That problem, Liang argues, is a lack of funding for critical biodefense programs which Congress passed in 2004 as a way to prepare us for biological agents like anthrax, smallpox, and Ebola, as well as chemical, radiological, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,